Extensive AAV and lentiviral vector production capabilities & expertise
Yposkesi is a full-service CDMO, providing professional support through all stages of gene therapy development. We make available the entire viral vector manufacturing services necessary to enable you to rapidly and successfully develop ATMPs. You gain access to specialized expertise with integrated project management as well as streamlined and cost-efficient bioprocess development services:
GMP manufacturing of clinical & commercial batches
Yposkesi has four independent GMP manufacturing suites where we perform either adherent (using 24CF10 cell factories) or suspension (up to 2*200L single use bioreactors) production processes. These suites are spacious enough to accommodate the installation of additional specific equipment, such as large single-use bioreactors (upto 500-1000L scale) as well as additional chromatography steps. These suites are Grade C and are operated at Biosafety level 2. Typical purification steps performed in these GMP manufacturing areas include depth filtration, tangential flow filtration, chromatography (affinity, ion-exchange, and size exclusion).
The facility has an operational capacity of up to 33 batches per year, and Yposkesi is extending this capacity. By 2023, Yposkesi’s global footprint will double to 100,000 sq ft (approx. 10,000 m2) with a second large-scale facility designed for commercial production and in compliance with EMA and FDA regulations. Yposkesi invests significantly in innovation and bioprocessing to deliver on high quality and cost-effective production.